Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
News and updates for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) focus on its activities in neurological and rare diseases, including commercial performance and clinical development. Company press releases highlight revenue trends from its marketed medicines NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as guidance ranges for total revenues and net product sales.
Investors following ACAD news can see announcements of quarterly financial results, participation in major healthcare and investor conferences, and business updates presented at events such as the J.P. Morgan Healthcare Conference. These updates often describe how NUPLAZID and DAYBUE are performing commercially and how Acadia views the growth outlook for its neurology and neuro‑rare franchises.
Acadia’s news flow also covers regulatory and clinical milestones. Examples include U.S. Food and Drug Administration approval of DAYBUE STIX, a powder formulation of trofinetide for oral solution for Rett syndrome in adults and pediatric patients 2 years of age and older, approval of DAYBUE oral solution by the Ministry of Health in Israel, and progress toward regulatory opinions and late‑stage studies for trofinetide in other regions. The company issues updates on its pipeline, such as timelines for Phase 2 and Phase 3 trials of remlifanserin (ACP‑204) in Alzheimer’s disease psychosis and Lewy body dementia psychosis, and data presentations on ACP‑711 and NUPLAZID at scientific congresses.
Readers of this ACAD news page can use it to track Acadia’s financial disclosures, regulatory approvals, clinical trial readouts, and strategic commentary from management over time. The news archive provides context on how the company’s commercial portfolio and pipeline in central nervous system and neuro‑rare diseases are evolving.
Acadia Pharmaceuticals (Nasdaq: ACAD) appointed Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Audit Committee and brings senior biopharma finance experience, including his role as SVP, Finance at Vertex since March 2020.
This board addition is positioned to strengthen financial and operational oversight as Acadia advances its commercial portfolio and pipeline across neurological and rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) said on March 2, 2026 that the EMA CHMP issued a negative opinion on trofinetide for Rett syndrome; the company intends to request a re-examination.
Acadia noted the pivotal LAVENDER trial met its co-primary and key secondary endpoints, while CHMP raised concerns about effect magnitude at 12 weeks, symptom coverage, and longer-term discontinuations. Trofinetide is approved in the US, Canada and Israel.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q4 2025 GAAP total revenues of $284M and FY2025 GAAP total revenues of $1.07B, representing 9% and 12% YoY growth. Non‑GAAP adjusted FY2025 revenues were $1.08B. Q4 NUPLAZID GAAP net sales were $174M and DAYBUE GAAP net sales were $110M.
The company recorded a $20M IRA rebate change in estimate affecting NUPLAZID GAAP sales; FY2026 guidance calls for $1.22–$1.28B total revenues and NUPLAZID sales of $760–$790M.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in three investor events in March 2026, including TD Cowen's 46th Annual Health Care Conference and The Citizens Life Sciences Conference.
Fireside chats are scheduled for March 2, 2026 at 11:10 a.m. ET in Boston and March 11, 2026 at 1:05 p.m. ET in Miami Beach. Live webcasts and archived recordings will be available on the company website for about one month after each presentation.
Acadia Pharmaceuticals (Nasdaq: ACAD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after U.S. market close. Management will host a conference call and webcast on February 25, 2026 at 4:30 p.m. ET, available via the company's investor website and archived through May 24, 2026.
Registration is required for dial-in details and a unique PIN; the webcast link will be posted on acadia.com under Investors.
Acadia Pharmaceuticals (NASDAQ: ACAD) said the CHMP at the European Medicines Agency issued a negative trend vote on its Marketing Authorization Application for trofinetide for Rett syndrome following an oral explanation.
Acadia expects a negative opinion, intends to request a CHMP re-examination once the opinion is formally adopted, and noted trofinetide is approved in the US, Canada, and Israel with >1,000 patients on active treatment globally.
Acadia Pharmaceuticals (Nasdaq: ACAD) provided business and pipeline updates at the 44th J.P. Morgan Healthcare Conference on January 13, 2026. Management reiterated a 2028 projected combined net sales of ~$1.7 billion (NUPLAZID ~ $1.0B; DAYBUE ~ $0.7B). Key near‑term catalysts include top‑line Phase 2 RADIANT results for remlifanserin expected Aug–Oct 2026 and multiple regulatory milestones for trofinetide (DAYBUE), including FDA approval of DAYBUE STIX (Dec 12, 2025) with limited U.S. availability in Q1 2026 and broader launch in Q2 2026.
Other items: Israel approval for DAYBUE oral solution, EMA CHMP opinion anticipated Q1 2026, Japan Phase 3 trofinetide readout expected Oct 2026–Mar 2027, and plans to initiate five Phase 2/3 studies with four readouts by end of 2027.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. Catherine Owen Adams, Chief Executive Officer, will speak on Tuesday, January 13, 2026 at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of the presentation will be available on the company website under Investors, with an archived recording accessible for approximately one month after the event.
Acadia’s commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and the company is developing mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced FDA approval of DAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation for treating Rett syndrome in patients aged 2 years and older.
The approval is supported by a bioequivalence study showing comparable exposure to DAYBUE oral solution and relies on efficacy/safety from the LAVENDER study. DAYBUE STIX will launch on a limited basis in Q1 2026 and more broadly in early Q2 2026. The original oral solution will remain available.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. ET. A live webcast will be available on the company website under the Investors section, and an archived recording will be accessible for approximately one month after the presentation.
Acadia highlighted its commercial portfolio, including FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and noted mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, plus earlier-stage programs in other neurological and rare diseases.